Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase

Bone Marrow Transplantation
D GallardoA Grañena

Abstract

Based on previous experiences in animals and humans, low doses of CD8+ lymphocytes infused together with the marrow graft seem to enhance engraftment after allogeneic T cell-depleted marrow transplantation. From April 1994 to February 1997, 12 patients with chronic myelogenous leukemia in first chronic phase receiving a bone marrow transplant (BMT) from an HLA-identical sibling were included in a pilot study of T cell subset depletion. Total depletion of CD4+ cells of the marrow graft and partial depletion of CD8+ cells was performed by immunomagnetic separation. In order to improve the engraftment rate, we infused a low fixed number of CD8+ lymphocytes (0.25 x 10(6)/kg). All the patients were at high risk of developing acute graft-versus-host disease (GVHD), with a recipient age of >30 years, and/or donor sensitized by previous pregnancies or transfusions. All of them received cyclosporin A and methotrexate post-BMT. No graft failure was observed. The grade III-IV GVHD rate was 16.6%, and the actuarial survival at 3 years is 81.8%. Immunological recovery showed persistent CD8+ HLA-DR+ lymphocytosis 8 months after transplant. Relapses were not observed. This experience shows the importance of CD8+ cells to ensure correct engraf...Continue Reading

Citations

Apr 9, 2002·Experimental Hematology·Akaru IshidaMakio Ogawa
Apr 18, 2007·Nature Reviews. Immunology·Warren D Shlomchik
May 14, 2008·Experimental Hematology·Ben J Jones, Steven J McTaggart
Feb 21, 2006·Histopathology·A M W van MarionJ G van den Tweel
Mar 25, 2014·Journal of Cellular and Molecular Medicine·Ana Valéria Gouveia de AndradeTorsten Tonn
Aug 11, 2001·Bone Marrow Transplantation·I AncínA Grañena
Aug 24, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·J ThieleH E Schaefer
Jul 17, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jun LongJiong Hu
Mar 25, 2009·International Journal of Immunopathology and Pharmacology·M D' AsaroN Caccamo
Dec 18, 2020·Frontiers in Immunology·Kutaiba Alhaj HussenBruno Canque

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.